Literature DB >> 11770220

First report of the Italian register for diffuse infiltrative lung disorders (RIPID).

C Agostini1, C Albera, F Bariffi, M De Palma, S Harari, M Lusuardi, A Pesci, V Poletti, L Richeldi, G Rizzato, A Rossi, M Schiavina, G Semenzato, C Tinelli.   

Abstract

RIPID was established in 1998 as a joint project of the major Italian scientific societies for Respiratory Medicine, with the aim to create an Italian Register on diffuse infiltrative lung disorders that can provide the basis for epidemiological and clinical studies of adequate sample size. In the period from May 1998 to December 2000, 1,382 cases were submitted from 54 Centers in 15 regions of Italy, 54.2% males (mean age +/- SD 50.5 +/- 16.8 years) and 45.8% females (50.2 +/- 15.3 years). A current smoking habit emerges in 18% of subjects; former smokers and never-smokers represent 26% and 56% of the total case series, respectively. The most frequent disease registered is idiopathic pulmonary fibrosis (37.6%), followed in decreasing order by sarcoidosis (29.2%), and Langherans' cell hystiocytosis (6.6%). High resolution computed tomography (HRCT) was considered as the most important tool for final diagnosis in the majority of cases (74.4%); 39.4% of patients underwent transbronchial biopsies, 39.2% bronchoalveolar lavage (BAL). A surgical biopsy was performed in 20.5% of patients. A web site has been activated from December 2000 (www.pneumonet.it/ripid), allowing prompt access to all information and scientific material concerning the project and to an electronic form for data collection that can be completed on-line.

Entities:  

Mesh:

Year:  2001        PMID: 11770220

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  12 in total

1.  Epidemiology of organising pneumonia in Iceland.

Authors:  G Gudmundsson; O Sveinsson; H J Isaksson; S Jonsson; H Frodadottir; T Aspelund
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

2.  Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study.

Authors:  Evans R Fernández Pérez; Craig E Daniels; Darrell R Schroeder; Jennifer St Sauver; Thomas E Hartman; Brian J Bartholmai; Eunhee S Yi; Jay H Ryu
Journal:  Chest       Date:  2009-09-11       Impact factor: 9.410

3.  Sarcoidosis in an Italian province. Prevalence and environmental risk factors.

Authors:  Deborah Beghè; Luca Dall'Asta; Claudia Garavelli; Augusto Alberto Pastorelli; Marilena Muscarella; Gloria Saccani; Marina Aiello; Ernesto Crisafulli; Massimo Corradi; Paolo Stacchini; Alfredo Chetta; Giuseppina Bertorelli
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

4.  Spectrum of interstitial lung diseases at a tertiary center in a developing country: A study of 803 subjects.

Authors:  Sahajal Dhooria; Ritesh Agarwal; Inderpaul Singh Sehgal; Kuruswamy Thurai Prasad; Mandeep Garg; Amanjit Bal; Ashutosh Nath Aggarwal; Digambar Behera
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

5.  Cryptogenic Organizing Pneumonia: Evolution of Morphological Patterns Assessed by HRCT.

Authors:  Francesco Tiralongo; Monica Palermo; Giulio Distefano; Ada Vancheri; Gianluca Sambataro; Sebastiano Emanuele Torrisi; Federica Galioto; Agata Ferlito; Giulia Fazio; Pietro Valerio Foti; Letizia Antonella Mauro; Carlo Vancheri; Stefano Palmucci; Antonio Basile
Journal:  Diagnostics (Basel)       Date:  2020-04-29

Review 6.  The epidemiology of interstitial lung disease and its association with lung cancer.

Authors:  G Raghu; F Nyberg; G Morgan
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

7.  Interstitial lung diseases in Saudi Arabia: A single-center study.

Authors:  Esam H Alhamad
Journal:  Ann Thorac Med       Date:  2013-01       Impact factor: 2.219

Review 8.  Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data.

Authors:  Jaana Kaunisto; Eija-Riitta Salomaa; Ulla Hodgson; Riitta Kaarteenaho; Marjukka Myllärniemi
Journal:  BMC Pulm Med       Date:  2013-08-20       Impact factor: 3.317

9.  Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy.

Authors:  Sergio Harari; Fabiana Madotto; Antonella Caminati; Sara Conti; Giancarlo Cesana
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

10.  Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Authors:  Kevin R Flaherty; Kevin K Brown; Athol U Wells; Emmanuelle Clerisme-Beaty; Harold R Collard; Vincent Cottin; Anand Devaraj; Yoshikazu Inoue; Florence Le Maulf; Luca Richeldi; Hendrik Schmidt; Simon Walsh; William Mezzanotte; Rozsa Schlenker-Herceg
Journal:  BMJ Open Respir Res       Date:  2017-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.